Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer

Gastric Cancer

Volumn 10, Issue 2, 2007, Pages 129-134

  Yamanaka, Takeharu ^a   Matsumoto, Shigemi ^b   Teramukai, Satoshi ^b,c   Ishiwata, Ryota ^c   Nagai, Yoji ^c   Fukushima, Masanori ^b,c  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Translational Research Informatics Center   (Japan)

Author keywords

Adverse effects; Gastric cancer; Risk factors; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; MITOMYCIN C;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; CONFERENCE PAPER; CREATININE CLEARANCE; DIARRHEA; FATIGUE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERBILIRUBINEMIA; JAPAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; RISK; RISK FACTOR; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; UNIVARIATE ANALYSIS; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CREATININE; DRUG COMBINATIONS; FEMALE; HEALTH SURVEYS; HUMANS; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; NEUTROPHILS; OXONIC ACID; PLATELET COUNT; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR;

EID: 34250777253     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-007-0422-y     Document Type: Conference Paper

References (18)

1. T Shirasaka Y Shimamato H Ohshimo M Yamaguchi T Kato K Yonekura 1996 Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548 57
2. T Shirasaka Y Shimamoto M Fukushima 1993 Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 4004 9
3. Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715 20
4. W Koizumi M Kurihara S Nakano K Hasegawa 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer: for the S-1 Cooperative Gastric Cancer Study Group Oncology 58 191 7
5. Furuse J, Okusaka T, Funakoshi A, Boku N, Yamao K, Ohkawa S, et al. A phase II study of S-1 in patients with metastatic pancreatic cancer. Proc Am Soc Clin Oncol 2005;23:abstract 4104
6. K Shirao A Ohtsu H Takada Y Mitachi K Hirakawa N Horikoshi 2004 Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma Cancer 100 2355 61
7. T Saek S Takashima M Sano N Horikoshi S Miura S Shimizu 2004 A phase II study of S-1 in patients with metastatic breast cancer - a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group Breast Cancer 11 194 202
8. M Kawahara K Furuse Y Segawa K Yoshimori K Matsui S Kudoh 2001 Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer Br J Cancer 85 939 43
9. Y Inuyama A Kida M Tsukuda N Kohno B Satake 2001 Late phase II study of S-1 in patients with advanced head and neck cancer Jpn J Cancer Chemother 28 1381 90
10. A Ohtsu H Baba Y Sakata Y Mitachi N Horikoshi K Sugimachi 2000 Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma; S-1 Cooperative Colorectal Carcinoma Study Group Br J Cancer 83 141 5
11. F Nagashima A Ohtsu S Yoshida K Ito 2005 Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer Gastric Cancer 8 6 11
12. Grading of toxicity. In: Wittes RE, editor. Manual of oncology therapeutics. Philadelphia: Lippincott; 1991. p. 445-8
13. Japan Society of Clinical Oncology 1997 Adverse drug reaction criteria of the Japan Society of Clinical Oncology Int J Clin Oncol 2 177 9
14. D Hosmer S Lemeshow 2000 Applied logistic regression 2nd edition Wiley New York
15. DW Cockcroft MH Gault 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 31 41
16. J Cassidy C Twelves E Van Cutsem P Hoff E Bajetta M Boyer 2002 First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin Ann Oncol 13 5669 75
17. RC Kane AT Farrell H Saber S Tang G Williams JM Jee 2006 Sorafenib for the treatment of advanced renal cell carcinoma Clin Cancer Res 12 7271 8
18. T Taguchi Y Inuyama R Kanamaru K Hasegawa S Akazawa H Niitani 1997 Phase I study of S-1; S-1 Study Group Jpn J Cancer Chemother 24 2253 64